Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 22 min ago
Peer-reviewedCC BY 4.0Frontiers in Endocrinology

MASLD VCTE-C cohort: a prospective multicenter study linking liver fibrosis to cardiovascular outcomes in patients with metabolic dysfunction–associated steatotic liver disease

11 affiliations
  1. 1Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine
  2. 2Department of Internal Medicine, Korea University Ansan Hospital
  3. 3Department of Internal Medicine, Chung-Ang University Hospital
  4. 4Center for Liver and Pancreatobiliary Cancer, National Cancer Center
  5. 5Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea
  6. 6Department of Internal Medicine, Seoul National University Hospital
  7. 7Department of Internal Medicine, Kyungpook National University Hospital
  8. 8Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine
  9. 9Department of Internal Medicine, Soonchunhyang University Bucheon Hospital
  10. 10Department of Internal Medicine, Hanyang University Hospital
  11. 11Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine

Abstract

Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) is associated with increased risk of cardiovascular disease (CVD). The MASLD vibration-controlled transient elastography (VCTE)-C cohort is designed to examine the relationships among VCTE-derived hepatic measures, coronary artery calcification, and long-term cardiovascular outcomes in patients with MASLD.

Methods: This prospective, multicenter observational cohort will enroll 880 patients with VCTE-defined MASLD (controlled attenuation parameter [CAP] ≥248 dB/m) across 11 tertiary hospitals in the Republic of Korea. Additional eligibility criteria include at least one of the following: (i) type 2 diabetes; (ii) prediabetes; or (iii) obesity accompanied by at least one additional cardiovascular risk factor. Baseline assessments include noninvasive surrogates for liver fibrosis (fibrosis-4 index and liver stiffness measurement by VCTE) and steatosis (CAP by VCTE), coronary artery calcium scoring by noncontrast cardiac computed tomography, cardiometabolic profiling, and 10-year cardiovascular risk estimation primarily using the PREVENT equations, with the Pooled Cohort Equations and K-CVD model applied as complementary tools.

Outcomes: The primary outcome is time to the first occurrence of a four-component major adverse cardiovascular event, comprising acute myocardial infarction, stroke, cardiovascular death, or coronary revascularization. Secondary outcomes include other cardiovascular events, hepatic and renal outcomes, extrahepatic malignancy, and all-cause mortality. Participants will be followed for up to 10 years with serial VCTE; repeat coronary artery calcium scoring is planned at 5 and 10 years in eligible participants.

Conclusion: The MASLD VCTE-C cohort is expected to provide prospective evidence on liver–cardiovascular relationships that may inform integrated risk assessment in patients with MASLD. (KCT0012473).

Related

  1. Comparative Efficacy and Safety of Saroglitazar and Dapagliflozin on Hepatic Steatosis and Glycemic Control in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A 25-Week Prospective Multicenter Comparative Cohort Study.
    Mukulesh Gupta, Kumar Prafull Chandra, Rajiv Awasthi +4
    Endocrinology, diabetes & metabolismPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMCPMC
  2. Cumulative estimated glucose disposal rate and longitudinal eGDR patterns in relation to incident cardiovascular disease among middle-aged and older adults with metabolic dysfunction-associated steatotic liver disease: a prospective cohort study
    Yiming Lin, Guohua Dai, Hui Guan +6
    Cardiovascular DiabetologyPeer-reviewedCC BY-NC-ND 4.0Full textEndocrinology & metabolismPMC
  3. Metabolic and Renal Dysfunction Are Associated With Intraplaque Lipid Burden Assessed by Near‐Infrared Spectroscopy Intravascular Ultrasound: Insights Into the Cardiovascular–Kidney–Metabolic Axis
    Hyungdon Kook, Woohyeun Kim, Seong Rae Cho +1
    Journal of the American Heart AssociationPeer-reviewedLicence not statedCardiovascular medicineCrossref
  4. Risk assessment of cardiovascular disease-related mortality in metabolic dysfunction-associated steatotic liver disease
    Donghee Kim, Pojsakorn Danpanichkul, Do Han Kim +3
    Clinical and Molecular HepatologyPeer-reviewedCC BY-NC 3.0Full text1 citedGeneral medicinePMC
  5. Dose-dependent efficacy and renal safety of pemafibrate versus fenofibrate in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridemia: a multicenter randomized controlled, open label trial
    Michihiro Iwaki, Hiroshi Tobita, Yuya Seko +38
    eClinicalMedicinePeer-reviewedCC BY-NC-ND 4.0Epidemiology & public healthCrossref
BibTeX
@article{chang2026masld,
  title = {{MASLD VCTE-C cohort: a prospective multicenter study linking liver fibrosis to cardiovascular outcomes in patients with metabolic dysfunction–associated steatotic liver disease}},
  author = {Young Chang and Young Kul Jung and Han Ah Lee and Yuri Cho and Ji Won Han and Su Jong Yu and Soo Young Park and Won-Mook Choi and Sang Gyune Kim and Dae Won Jun and Seung Up Kim},
  journal = {Frontiers in Endocrinology},
  year = {2026},
  month = nov,
  doi = {10.3389/fendo.2026.1976585},
  url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1976585/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - MASLD VCTE-C cohort: a prospective multicenter study linking liver fibrosis to cardiovascular outcomes in patients with metabolic dysfunction–associated steatotic liver disease
AU  - Young Chang
AU  - Young Kul Jung
AU  - Han Ah Lee
AU  - Yuri Cho
AU  - Ji Won Han
AU  - Su Jong Yu
AU  - Soo Young Park
AU  - Won-Mook Choi
AU  - Sang Gyune Kim
AU  - Dae Won Jun
AU  - Seung Up Kim
PY  - 2026
DA  - 2026/11/12
JO  - Frontiers in Endocrinology
DO  - 10.3389/fendo.2026.1976585
UR  - https://www.frontiersin.org/articles/10.3389/fendo.2026.1976585/full
AB  - Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) is associated with increased risk of cardiovascular disease (CVD). The MASLD vibration-controlled transient elastography (VCTE)-C cohort is designed to examine the relationships among VCTE-derived hepatic measures, coronary artery calcification, and long-term cardiovascular outcomes in patients with MASLD.  Methods: This prospective, multicenter observational cohort will enroll 880 patients with VCTE-defined MASLD (controlled attenuation parameter [CAP] ≥248 dB/m) across 11 tertiary hospitals in the Republic of Korea. Additional eligibility criteria include at least one of the following: (i) type 2 diabetes; (ii) prediabetes; or (iii) obesity accompanied by at least one additional cardiovascular risk factor. Baseline assessments include noninvasive surrogates for liver fibrosis (fibrosis-4 index and liver stiffness measurement by VCTE) and steatosis (CAP by VCTE), coronary artery calcium scoring by noncontrast cardiac computed tomography, cardiometabolic profiling, and 10-year cardiovascular risk estimation primarily using the PREVENT equations, with the Pooled Cohort Equations and K-CVD model applied as complementary tools.  Outcomes: The primary outcome is time to the first occurrence of a four-component major adverse cardiovascular event, comprising acute myocardial infarction, stroke, cardiovascular death, or coronary revascularization. Secondary outcomes include other cardiovascular events, hepatic and renal outcomes, extrahepatic malignancy, and all-cause mortality. Participants will be followed for up to 10 years with serial VCTE; repeat coronary artery calcium scoring is planned at 5 and 10 years in eligible participants.  Conclusion: The MASLD VCTE-C cohort is expected to provide prospective evidence on liver–cardiovascular relationships that may inform integrated risk assessment in patients with MASLD. (KCT0012473).
SN  - 1664-2392
ER  -